Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Eco Wave Power advances 1 MW Portugal wave energy project as APDL starts Barra do Douro breakwater repairs

Eco Wave Power advances 1 MW Portugal wave energy project as APDL starts Barra do Douro breakwater repairs

ReutersReuters2026/08/13 12:32
  • Eco Wave Power advanced its planned 1 MW onshore wave energy project in Porto as APDL began rehabilitating the Barra do Douro breakwater.
  • Works follow storm damage, affecting the coastal infrastructure designated for the installation, with timing now tied to breakwater completion.
  • CEO Inna Braverman will meet APDL in mid-August to align the completion schedule with installation readiness for the first phase.
  • APDL agreed to issue a support letter for a request to extend the grid-connection deadline for the 1 MW phase.
  • The APDL agreement allows development of up to 20 MW in Portugal, with the 1 MW installation positioned as the initial step.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eco Wave Power Global AB (publ) published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-088725), on August 13, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well

Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.

智通财经2026/09/07 07:31
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well